Citigroup’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-56,656
| Closed | -$1.9M | – | 6197 |
|
|
2026
Q1 | $1.9M | Buy |
56,656
+21,993
| +63% | +$862K | ﹤0.01% | 2693 |
|
|
2025
Q4 | $1.6M | Buy |
34,663
+11,740
| +51% | +$644K | ﹤0.01% | 2804 |
|
|
2025
Q3 | $1.55M | Sell |
22,923
-2,544
| -10% | -$189K | ﹤0.01% | 2879 |
|
|
2025
Q2 | $2.13M | Sell |
25,467
-29,651
| -54% | -$2.22M | ﹤0.01% | 2581 |
|
|
2025
Q1 | $3.94M | Buy |
55,118
+1,285
| +2% | +$62.6K | ﹤0.01% | 2133 |
|
|
2024
Q4 | $2.42M | Buy |
53,833
+36,785
| +216% | +$1.91M | ﹤0.01% | 2655 |
|
|
2024
Q3 | $861K | Buy |
17,048
+6,100
| +56% | +$292K | ﹤0.01% | 3368 |
|
|
2024
Q2 | $447K | Sell |
10,948
-86,806
| -89% | -$3.68M | ﹤0.01% | 3468 |
|
|
2024
Q1 | $4.18M | Buy |
97,754
+63,792
| +188% | +$2.89M | ﹤0.01% | 1835 |
|
|
2023
Q4 | $1.37M | Buy |
33,962
+33,859
| +32,873% | +$963K | ﹤0.01% | 2568 |
|
|
2023
Q3 | $3.04K | Buy |
+103
| New | +$623 | ﹤0.01% | 4856 |
|
|
2023
Q1 | – | Sell |
-100
| Closed | -$198 | – | 5824 |
|
|
2022
Q4 | $198 | Buy |
+100
| New | +$124 | ﹤0.01% | 5599 |
|
|
2022
Q3 | – | Sell |
-35
| Closed | – | – | 6277 |
|
|
2022
Q2 | $0 | Buy |
+35
| New | +$97 | ﹤0.01% | 6622 |
|
|
2021
Q2 | – | Sell |
-263
| Closed | -$5K | – | 6375 |
|
|
2021
Q1 | $5K | Sell |
263
-479
| -65% | -$15.4K | ﹤0.01% | 5907 |
|
|
2020
Q4 | $21K | Buy |
742
+551
| +288% | +$15.9K | ﹤0.01% | 6619 |
|
|
2020
Q3 | $7K | Sell |
191
-100
| -34% | -$2.92K | ﹤0.01% | 6850 |
|
|
2020
Q2 | $10K | Buy |
+291
| New | +$12.6K | ﹤0.01% | 7062 |
|
|
2016
Q2 | – | Sell |
-1
| Closed | – | – | 7399 |
|
|
2016
Q1 | $0 | Buy |
+1
| New | +$98 | ﹤0.01% | 7729 |
|
|
2015
Q3 | – | Sell |
-4
| Closed | -$1K | – | 7681 |
|
|
2015
Q2 | $1K | Sell |
4
-11
| -73% | -$4.23K | ﹤0.01% | 7329 |
|
|
2015
Q1 | $7K | Buy |
+15
| New | +$4.45K | ﹤0.01% | 6611 |
|
Citigroup's SLNO Position: Q2 2026 in Review
Citigroup sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 56,656 shares — an estimated $1.9M sold.
Citigroup first reported a position in SLNO in Q1 2015 and held it in 20 quarters. The position peaked at $4.18M in Q1 2024. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- Citigroup reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- Citigroup sold 56,656 Soleno Therapeutics shares in Q2 2026, an estimated $1.9M.
- Citigroup first reported a position in Soleno Therapeutics in Q1 2015 and held it in 20 quarters.
- Citigroup's Soleno Therapeutics position peaked at $4.18M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.